Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases

Can We Use Routinely Collected Healthcare Data for a Nationwide Trial on Venous Thromboembolism Prophylaxis Following Primary Joint Replacement? A Feasibility Study

“…130 Therefore there will be variability between the quality of HAT registers between hospitals, 131 which will have implications for accuracy and data quality. However our findings do now 132 question the accuracy of previous reports that have relied on HAT registers to identify VTEs 133 following arthroplasty, 11 and findings from these previous studies must be interpreted with 134 caution until the respective centres have assessed the accuracy of their own HAT registers for 135…”

Aspirin as venous thromboembolism prophylaxis in total joint arthroplasty: a narrative review of the current evidence

“…One study utilized daily Rivaroxaban 10 mg (Bayer Pharma, Titusville, NJ) for 5 days after surgery, then transitioned the patients to ASA 81 mg daily 8. Another study utilized low-molecular weight heparin (Sanofi-Aventis, Bridgewater, NJ) while in the hospital, then transitioned the patients to ASA 150 mg upon hospital discharge 9. There was wide heterogeneity in the studies with regard to adjunct modalities for VTE prophylaxis: thromboembolism deterrent (TED) stockings, mechanical compression devices (MCD), and early postoperative mobilization.…”

“…The second lowest clinical rate of VTE was found in the patients who received ASA in contrast to other forms of chemoprophylaxis. Ghosh et al 9 reported 0.88% symptomatic VTE rate using outpatient ASA 150 mg for 6 wk in a cohort of 3294 patients after TKAs. These patients received low-molecular-weight heparin while in the hospital.…”

“…The reported rates of major bleeding related to using ASA as VTE prophylaxis after TKAs range from 0.13% to 1.20%. [8][9][10][11][12][13] Faour et al 13 reported the major bleeding rates of 0.23% and 0.16% with the use of low-dose (81 mg), and high-dose (325 mg), respectively. Parvizi et al 20 reported no difference in the rate of gastrointestinal ulceration between the low-dose and the high-dose groups (0.3% and 0.5%, respectively) in TKA patients.…”

“…The overall PJI rates reported in the patients who received ASA ranged from 0.1% to 0.5%. 9,11,19,20 Haung et al 19 evaluated a registry of both TKA and THA patients and reported significantly lower PJI rate in the patients who received ASA (0.4%) compared with those who received adjusted-dose warfarin (1.5%) (OR 2.77, 95% CI 1.19 to 6.45). Radzak et al 14 in contrast reported higher PJI and surgical site infection rates in patients who received ASA (6.1%) after TKA compared with those who received enoxaparin (1.7%, P = 0.04).…”